Drugs / GS-6620
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01316237 | Jan → Oct 2011 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-6620 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01316237 ↗ |
| Modality | Small molecule | — CHEMBL3120793 ↗ |
| Route | Oral | “as an oral solution, BID” NCT01316237 ↗ |